EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-SA 4.0

Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis

Sarjak M Shah, Priya Prabhu, Jyotirmay Biswas

Indian Journal of Ophthalmology · 2025

DOI: 10.4103/ijo.ijo_712_24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Sarjak M Shah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shri Bhagwan Mahavir Vitreoretinal Services, Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Drug Implants, Uveitis, Posterior, Glucocorticoids, Intravitreal Injections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of intermediate and posterior uveitis poses a significant challenge of achieving adequate drug concentrations in the posterior segment over the chronic nature of the disease. Systemic agents seldom reach effective drug levels, and even with low maintenance or tapering doses, it is hard to avoid systemic toxicity. The use of intravitreal and periocular injections is often unable to prevent recurrences due to their short half-life. Since the emergence of intravitreal implants (Vitrasert, Retisert), it has become possible to circumvent these therapeutic challenges. A detailed review in the PubMed index yielded 155 articles, of which 22 were analyzed based on exclusion criteria. A recent shift from surgically sutured to minimally invasive injectable implants mainly indicated for noninfectious uveitis is evident from the literature. This review article also provides insights into dexamethasone (Ozurdex) and recent fluocinolone acetonide (Yutiq, Iluvien) implants with particular emphasis on their improved safety and efficacy. Dexamethasone implants favor the therapeutic goal of prevention of recurrences, whereas the use of fluocinolone implants helps to attain better visual outcomes due to their longer duration of action. Thus, the review provides recent literature supporting the role and indication of sustained release intravitreal implants in the management of noninfectious intermediate and posterior uveitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ImplantsUveitis, PosteriorGlucocorticoidsIntravitreal InjectionsUveitis, IntermediateHumansDexamethasoneFluocinolone AcetonideVisual Acuity

Substanzen

Drug ImplantsGlucocorticoidsDexamethasoneFluocinolone Acetonide

Autor:innen und Institutionen

  • Shri Bhagwan Mahavir Vitreoretinal Services, Chennai, Tamil Nadu, India.
  • Department of Uveitis and Ocular Pathology, Sankara Nethralaya, Nungambakkam, Chennai, Tamil Nadu, India.

Zitieren

APA

Shah, S. M., Prabhu, P., & Biswas, J. (2025). Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_712_24

Vancouver

Shah SM, Prabhu P, Biswas J. Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_712_24

BibTeX
@article{Shah2025,
  author = {Shah, Sarjak M and Prabhu, Priya and Biswas, Jyotirmay},
  title = {Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis},
  journal = {Indian Journal of Ophthalmology},
  year = {2025},
  doi = {10.4103/ijo.ijo_712_24}
}
Kostenlos starten →